Lecture 12 - Current and Future CF Therapies Flashcards

1
Q

What is a CF centre of excellence?

A

A centre with over 50 CF patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q
Physiotherapy techniques for CF
1)
2)
3)
4)
5)
A

1) Gravity assisted drainage
2) Active cycle of breathing techniques
3) Autogenic drainage
4) Positive expiratory pressure
5) Activity, exercise

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Two uses for antimicrobials in CF

A

Prophylactic, for exacerbations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the procedure for treating a severe infection in CF?

A

Take patient to hospital, put them on IV antibiotics for a few weeks

‘Tune up’

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Advantage of nebulised antimicrobials

A

Can be targeted directly to LRT

Lower dose can be used –> Reduced side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Ways to susceptibility test patient microbes

A

Sputum test

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How can resistance be avoided in CF patients?

A

Always give at least 2 different antibiotics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Difficulties in treating CF patients with antibiotics
1)
2)
3)

A

1) Side effects, especially from long-term use
2) Antibiotic resistance in bacteria
3) CF patients have different pharmacokinetics. Often need much higher doses, EG: aminoglycosides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Bacteria which can be spread between CF patients
1)
2)
3)

A

1) Pseudomonas
2) Burkholderia cepacia
3) MRSA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Way to reduce disease spread in hospitalised CF patients

A

Patient segregation - Don’t allow 2 CF patients to interact

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Mucolytics
1)
2)
3)

A

1) Recombinant human deoxyribonuclease-1 (pulmozyme)
2) Hypertonic saline
3) Mannitol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Effect of mannitol

A

Osmotic agent

Draws water into airway surface liqud

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Anti-inflammatory agents for CF
1)
2)
3)

A

1) Azithromycin
2) Glucocorticosteroids
3) NSAID - Ibuprofen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Issues with glucocorticosteroids and NSAID therapies

A

Many side-effects

EG: NSAIDs are nephrotoxic for long-term use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Energy requirements of CF patients

A

120-150% of normal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Proportion of CF diet that is fat

A

35-40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Pancreatic enzyme tablet

A

Creon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

When is creon taken?

A

With all foods containing fat, protein or complex carbohydrates

19
Q

Creon dose

A

500-2000 units of lipase/kg body weight/meal

20
Q

What is most CF antibiotic research focussed on?

A

Novel delivery systems

Can direct delivery of antibiotics can reduce side effects, increase microbicidal activity

21
Q

Sildenafil

A

Viagra

22
Q

Potential uses for sildenafil

A

Antiinflammation, treat chronic hypertension

23
Q

Novel antibiotic delivery mechanisms
1)
2)

A

1) Dry powder inhaler

2) Nebulised

24
Q
Future anti-inflammatory therapies for CF
1)
2)
3)
4)
A

1) Glutathione
2) Sildenafil
3) KB001A
4) Alpha-1 antitrypsin

25
Q

Glutathione therapy

A

Replaces glutathione, an important antioxidant

26
Q

What is sildenafil?

A

Phosphodiesterase inhibitor

27
Q

What is KB001?

A

A humanised monoclonal Fab fragment

Targets Pseudomonas virulence factor, reduces local inflammation

28
Q

What is alpha-1 antitrypsin?

A

An antiprotease

Can help resist overwhelming of antiproteases by neutrophil response

29
Q

Problems with gene therapy
1)
2)
3)

A

1) Lungs are still an effective barrier to foreign bodies
2) Viral vectors have caused deaths of some testing volunteers
3) Unmethylated CpG DNA on plasmid, which can cause mild flu-like symptoms

30
Q

Non-viral gene therapy vectors

A

Cationic liposomes complexed with plasmid DNA expressing CFTR

31
Q

Outcome of gene therapy trials
1)
2)
3)

A

1) Proof of concenpt
2) Most only stage I and II trials
3) Over 30 trials to date

32
Q

Problems with possible stem-cell therapy
1)
2)

A

1) Under 1% frequency of engraftment in lungs

2) Almost always causes severe lung damage

33
Q

Example of a successful protein rescue therapy

A

Ivacaftor

34
Q

Ivacaftor

A

Potentiator protein
Keeps defective class III mutation CFTR channel open
Corrects G551D mutation

35
Q

Positive aspects of Ivacaftor
1)
2)
3)

A

1) Significant improvement in lung function
2) Significant weight increase
3) Significant decrease in symptoms

36
Q

Proof that ivacaftor corrects underlying defect of type III CF

A

Chloride sweat values are normal

37
Q

Ivacaftor dosage

A

150mg tablet, twice daily

38
Q

Drawbacks of ivacaftor
1)
2)

A

1) $294,000 per patient per year

2) G551D affects 4% of patients worldwide

39
Q

What is lumacaftor?

A

A corrector, which is used to treat type II mutations

Increases F508del CFTR trafficked to cell surface

40
Q

Reason for combining lumacaftor and ivacaftor

A

Once type II proteins trafficked to surface, don’t function properly

41
Q

Efficacy of lumacaftor

A

CFTR transport 15% of wild type

42
Q

Efficacy of lumacaftor combined with ivacaftor

A

CFTR transport 30% of wild type

43
Q

Ataluren

A

A small molecule compound, promotes read-through of premature stop codons (type I mutation)